SCHEDULE: 12 West Capital Boosts Maravai LifeSciences Stake to 6.2%

12 West Capital Management LP and Joel Ramin have increased their beneficial ownership in Maravai LifeSciences Holdings, Inc. to 6.2% of Class A Common Stock.

Summary

• 12 West Capital Management LP and Joel Ramin collectively report beneficial ownership of 8,921,335 shares of Maravai LifeSciences Holdings, Inc. Class A Common Stock.
• This represents 6.2% of the company's Class A Common Stock outstanding.
• The ownership is primarily held through 12 West Capital Fund LP and 12 West Capital Offshore Fund LP.
• The calculation is based on 145,022,751 shares outstanding as of October 31, 2025, as reported in the Company's Form 10-Q.
• This filing is an Amendment No. 4, indicating previous ownership disclosures by the reporting persons.
• The Reporting Persons certify that the securities were not acquired for the purpose of changing or influencing control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional stake suggests confidence in the company's long-term value, without indicating any immediate operational changes or activist pressure.

Positives

• A significant institutional investor, 12 West Capital Management LP, maintains a substantial stake, indicating continued confidence in Maravai LifeSciences.
• The passive investment intent declared by the reporting persons suggests a long-term, non-activist approach, which can provide stability to the shareholder base.

Negatives

• No specific negative information is contained within this Schedule 13G filing, as it primarily reports beneficial ownership.

Risks

• No specific risks related to Maravai LifeSciences Holdings, Inc. are detailed in this beneficial ownership report. The filing focuses solely on the reporting persons' stake.

Future Outlook

This Schedule 13G filing does not provide specific forward-looking statements or guidance regarding Maravai LifeSciences Holdings, Inc.'s future performance or strategic direction. It solely reports the beneficial ownership stake of 12 West Capital Management LP and Joel Ramin.

Management Comments

• The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that a significant stake held by an institutional investor like 12 West Capital Management LP in a life sciences company such as Maravai LifeSciences can signal confidence in the sector's long-term growth prospects, particularly in areas related to biotechnology and research tools. This type of passive investment often reflects a belief in the company's underlying business model and market position within its niche.

Comparison to Industry Standards

• A 6.2% stake is a notable position for an institutional investor, placing 12 West Capital Management among the larger shareholders of Maravai LifeSciences.
• Compared to typical institutional holdings in the biotechnology and life sciences sector, a stake of this size is substantial enough to warrant attention, though it does not imply activist intent given the 13G filing type.
• For example, similar-sized passive stakes are often seen in established life sciences companies where large funds hold significant, but non-controlling, positions, such as in companies like Bio-Rad Laboratories or Sartorius AG.

Stakeholder Impact

• Shareholders: The continued significant stake by an institutional investor may provide a degree of confidence and stability in the company's stock.
• Management: The passive nature of the investment, as certified, suggests no immediate pressure for strategic or operational changes from this particular shareholder.

Next Steps

• No specific future actions or milestones for Maravai LifeSciences are mentioned in this beneficial ownership report.
• 12 West Capital Management LP will continue to report changes in its beneficial ownership as required by SEC regulations.

Key Dates

Recommendation

The filing indicates a stable, significant institutional holding in Maravai LifeSciences, suggesting continued confidence from a major investor. However, it does not provide new operational or financial data to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate for investors already in the stock, while new investors should conduct further due diligence beyond this ownership disclosure.

Keywords

Maravai LifeSciences, 12 West Capital Management, Joel Ramin, Beneficial Ownership, Class A Common Stock, SEC Filing, Schedule 13G, Institutional Investor, Biotechnology, Life Sciences